Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks IPOs and placings
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'
(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector. "We are positive on sector fundamentals but see 2024 headwinds: a relative scarcity of big catalysts, US political overhangs, and macro rotation," Jefferies said in a research note on Wednesday.
The broker said Swiss firm Novartis was still its top pick in the sector, but also rates French peer Sanofi as a 'buy'.
As for UK-listed GSK, analysts said its net present value suggests the stock is "deeply discounted", as it lifted its recommendation and target price by 23% to 1,900p.
Jefferies' GSK estimates for 2026 and beyond are "well above consensus" as it reckons profits are only likely to face a "blip, not cliff" when HIV patents expire in 2028. This is due to the company's long-acting HIV injectables, vaccines, and new pipeline launches, it said.
Turning to AstraZeneca, margin concerns are a downside for the stock, as Jefferies lowered its stance and cut its target pice by 12% to 11,000p.
The note said: "We argue AZN is primarily a top-line growth and pipeline story, with our above consensus revenues mitigating EPS risk. However, margin clarity may be needed for stock upside and 2024 has fewer major pipeline catalysts."
GSK was trading 1.4% higher at 1,501.1p by 1131 GMT, while AstraZeneca was down 1.1% at 10,672p.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.
